GSK and Relation Therapeutics expanded their collaboration to generate large-scale human cellular datasets and train AI models for drug target discovery. The agreement, worth up to $110 million, combines Relation’s Lab-in-the-Loop experimental workflows with models from its MORGAN platform to study how cells respond to genetic changes and drug interventions.
Relation will use techniques including tissue profiling, single-cell and spatial transcriptomics, sequencing, perturbation experiments and target validation, with machine learning applied to target identification and prioritization. The deal builds on earlier work between the companies in fibrotic diseases and osteoarthritis, where they combined human genetics, multi-omics and functional assays.
For drug developers, the partnership highlights the value of generating disease-specific biological data alongside model development. The approach could reduce dependence on heterogeneous public datasets while improving AI-supported target identification and experimental validation.
Image Credit: Relation Therapeutics
What's Driving This Trend
- Cellular Dataset Partnerships
- Pharma-AI collaborations centered on proprietary human cellular data create differentiation through disease-specific datasets that improve model relevance and target confidence.
- Lab-in-the-loop Discovery
- Integrated experimental workflows and machine learning systems compress discovery cycles by pairing predictive models with continuous biological validation.
- Spatial Multi-omics Targeting
- High-resolution profiling across single-cell, spatial, and genomic layers enables more precise identification of disease mechanisms and therapeutic intervention points.
Who This Affects Most
- Pharmaceutical Research
- Drug developers gain strategic advantage from proprietary biological datasets that support stronger target prioritization and lower translational risk.
- Biotechnology Platforms
- AI-enabled biotech firms are positioned to commercialize discovery infrastructure that combines wet-lab experimentation with scalable computational modeling.
- Genomics Analytics
- Advanced sequencing and transcriptomics providers benefit from growing demand for disease-specific data generation tied directly to therapeutic decision-making.
